AzTrials
AzTrials

Opioid UsePURFTNCT03749811

Pupillometry-guided Remifentanil Infusion Versus Conventional Administration in Children

A study testing Pupillometry in people with Opioid Use, run by Seoul National University Hospital at 1 site in South Korea.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Our study aims to compare the total intravenous dose of remifentanil per anesthesia hour and body weight in two groups of pediatric surgical patients - an interventional group with remifentanil infusion under pupillometry monitoring, and control group without pupillometry - to figure out whether pupillometry… Read more about this study

Who is it for?
Ages 3 to 12 years
Conditions the study is for
Opioid Use
What is being tested?
Pupillometry
Could I receive a placebo?
No, everyone receives an active treatment
How many people
60 participants
Where
1 siteSouth Korea
Study dates
4 Dec 2018to 18 Nov 2021
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 3 to 12 years
  • All sexes
  • No healthy volunteers
  • Child

Who may be able to join

  • Pediatric patients who are at 3 to 6 years of age, scheduled to undergo elective surgery with estimated time of operation 2 hours or longer, under general anesthesia
  • American Society of Anesthesiologists physical status classification (ASA class) I - II
  • Patient and his/her parents are willing to participate after explanation of the purpose, materials, methods, possible risks and benefits of the research

Who cannot join

  • History of hypersensitivity/allergic reaction to the drugs which are used in general anesthesia
  • Preoperative use of analgesics, antipsychotics and/or antiepileptics
  • Mental retardation
  • Medications related to hindrance of autonomic nerve system activity, e. g., beta blockers
  • Underlying ophthalmic diseases

Trial locations and contacts

1 site in 1 country.

Hee-Soo Kim, M.D., Ph.D. contact

+82-2-2072-3664

dami0605@snu.ac.kr

South Korea1 site, 1 recruiting
  • Seoul National University Hospital

    Seoul

    Heesoo Kim

    Recruiting

Other trials in South Korea

About this study

Official title: Comparison of Remifentanil Consumption in Pupillometry-guided Versus Conventional Administration in Pediatric Surgery: a Prospective, Randomized Controlled Trial

Our study aims to compare the total intravenous dose of remifentanil per anesthesia hour and body weight in two groups of pediatric surgical patients - an interventional group with remifentanil infusion under pupillometry monitoring, and control group without pupillometry - to figure out whether pupillometry monitoring may reduce remifentanil consumption during anesthesia while providing sufficient analgesia for surgical noxious stimuli.

Read the detailed description

comparison of total used opioid

Conditions
Opioid Use
Being tested
Pupillometry
Keywords
Pupil dilatory reflex, Remifentanil, Analgesia
Medical subject headings
Agnosia

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • PupillometryDevice

    After induction of anesthesia and determination of the loss of consciousness of the participant, baseline diameter of pupil is measured by electronic pupillometry device. During anesthesia, participant's pupil diameter is repeatedly measured with 5-minute interval. Pupil dilation of 30% or more compared to baseline is indicative of insufficient analgesia.

Study groups in NCT03749811
Study groupRoleWhat they receive
Pupillometry groupExperimentalA group of participants who receive remifentanil infusion under pupillometry monitoring.
Receives: Device: Pupillometry
Conventional groupNo interventionA group of participants who receive remifentanil infusion without pupillometry monitoring; their analgesic dose is mainly determined via hemodyamic change.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. remifentanil total dose in microgram

    Remifentanil total dose divided by anesthesia time (minute) and patient weight (kg).

    Measured: from beginning of anesthesia to the end of the anesthesia

  2. FLACC score

    FLACC score (a pain evaluation method for children who cannot express their severity of pain verbally) right after post-anesthesia care unit arrival.

    Measured: Arrival at the post-anesthesia care unit

  3. Adjusted analgesic dose after anesthesia

    Total dose of analgesics (NSAIDs and opioids) delivered to the patient since the end of the anesthesia, until 24 hours after the end of anesthesia

    Measured: 24 hours after the end of anesthesia

Secondary outcomes (2)
  1. Emergence time

    Time between the end of the surgery and extubation

    Measured: Intraoperative

  2. Incidence of rescue therapy

    Incidence of vasopressor/inotropics/anticholinergics/fluid/vasodilators administered, due to moderate to severe hemodynamic change

    Measured: Intraoperative

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted21 Nov 2018
  2. Study start4 Dec 2018
  3. Primary completion18 Nov 2020 (estimated)
  4. Study completion18 Nov 2021 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Single group
Model description
Interventional group: remifentanil infusion under pupillometry monitoring. Control group: remifentanil infusion without pupillometry monitoring (remifentanil dose is determined by conventional method, i. e., hemodynamic change probably related to noxious stimuli)
Masking
Triple blind
Who is masked
Participant, Investigator, Outcomes assessor
Enrolment
60 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03749811
Sponsor's protocol ID
1811-036-984
Acronym
PURFT
Status last verified
Mar 2019
First submitted
18 Nov 2018
Last updated
29 Mar 2019
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Wildemeersch D, Peeters N, Saldien V, Vercauteren M, Hans G. Pain assessment by pupil dilation reflex in response to noxious stimulation in anaesthetized adults. Acta Anaesthesiol Scand. 2018 Sep;62(8):1050-1056. doi: 10.1111/aas.13129. Epub 2018 Apr 19.

    PubMed 29671874
  • Sabourdin N, Barrois J, Louvet N, Rigouzzo A, Guye ML, Dadure C, Constant I. Pupillometry-guided Intraoperative Remifentanil Administration versus Standard Practice Influences Opioid Use: A Randomized Study. Anesthesiology. 2017 Aug;127(2):284-292. doi: 10.1097/ALN.0000000000001705.

    PubMed 28719527

Questions about this trial

What is this clinical trial studying?

A study testing Pupillometry in people with Opioid Use, run by Seoul National University Hospital at 1 site in South Korea.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 29 Mar 2019. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in South Korea. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Hee-Soo Kim, M.D., Ph.D. (+82-2-2072-3664, dami0605@snu.ac.kr), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

remifentanil total dose in microgram (time frame: from beginning of anesthesia to the end of the anesthesia). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT03749811, which also lists 2 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Mar 2019.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in